Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
98% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. AEZS: No Debt )
AEZS' s 10-Year Cash to Debt Range
Min: 0.44   Max: No Debt
Current: No Debt

F-Score: 2
Z-Score: -8.41
M-Score: -23.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) 128.40
AEZS's Operating margin (%) is ranked higher than
99% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. AEZS: 128.40 )
AEZS' s 10-Year Operating margin (%) Range
Min: -1448.42   Max: -8.58
Current: 128.4

-1448.42
-8.58
Net-margin (%) 33.50
AEZS's Net-margin (%) is ranked higher than
96% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. AEZS: 33.50 )
AEZS' s 10-Year Net-margin (%) Range
Min: -994.25   Max: 110.36
Current: 33.5

-994.25
110.36
ROE (%) -102.75
AEZS's ROE (%) is ranked higher than
57% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. AEZS: -102.75 )
AEZS' s 10-Year ROE (%) Range
Min: -706.89   Max: 123.98
Current: -102.75

-706.89
123.98
ROA (%) -25.59
AEZS's ROA (%) is ranked higher than
70% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. AEZS: -25.59 )
AEZS' s 10-Year ROA (%) Range
Min: -56.96   Max: 11.31
Current: -25.59

-56.96
11.31
ROC (Joel Greenblatt) (%) -2932.33
AEZS's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. AEZS: -2932.33 )
AEZS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1666.33   Max: -15.93
Current: -2932.33

-1666.33
-15.93
Revenue Growth (%) -52.70
AEZS's Revenue Growth (%) is ranked higher than
58% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. AEZS: -52.70 )
AEZS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 131.9
Current: -52.7

0
131.9
EBITDA Growth (%) -18.30
AEZS's EBITDA Growth (%) is ranked higher than
68% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AEZS: -18.30 )
AEZS' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 184
Current: -18.3

0
184
EPS Growth (%) -23.50
AEZS's EPS Growth (%) is ranked higher than
68% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AEZS: -23.50 )
AEZS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.3
Current: -23.5

0
65.3
» AEZS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AEZS Guru Trades in Q3 2013

Jim Simons 444,250 sh (+17.95%)
Murray Stahl 17,083 sh (unchged)
» More
Q4 2013

AEZS Guru Trades in Q4 2013

Jim Simons 896,445 sh (+101.79%)
Murray Stahl Sold Out
» More
Q1 2014

AEZS Guru Trades in Q1 2014

Jim Simons 44,150 sh (-95.07%)
» More
Q2 2014

AEZS Guru Trades in Q2 2014

Jim Simons 641,917 sh (+1353.95%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.90
AEZS's P/B is ranked higher than
58% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. AEZS: 6.90 )
AEZS' s 10-Year P/B Range
Min: 0.58   Max: 43.4
Current: 6.9

0.58
43.4
Current Ratio 0.95
AEZS's Current Ratio is ranked higher than
52% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. AEZS: 0.95 )
AEZS' s 10-Year Current Ratio Range
Min: 0.95   Max: 50.67
Current: 0.95

0.95
50.67
Quick Ratio 0.95
AEZS's Quick Ratio is ranked higher than
54% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. AEZS: 0.95 )
AEZS' s 10-Year Quick Ratio Range
Min: 0.95   Max: 49
Current: 0.95

0.95
49

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -99.00
AEZS's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. AEZS: -99.00 )
AEZS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.4   Max: -13.1
Current: -99

-16.4
-13.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AEZ.Canada, ET81.Germany
AEterna Zentaris, Inc., is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.
» More Articles for NAS:AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
comment on AEZS Oct 26 2011 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Nasdaq stocks posting largest volume increases Oct 23 2014
Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and... Oct 07 2014
Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and... Oct 07 2014
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New... Sep 02 2014
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New... Sep 02 2014
4 Stocks Under $10 to Trade Now Aug 15 2014
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results Aug 07 2014
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results Aug 07 2014
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in... Aug 06 2014
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in... Aug 06 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market Aug 05 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market Aug 05 2014
Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014 Jul 31 2014
12 Analyst Stocks to Buy Under $10 With Huge Potential Upside Jul 19 2014
Basket Of Biotech Bargains To Buy And Hold Jun 30 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto Jun 11 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto Jun 11 2014
Aeterna Zentaris announces workforce reduction and optimization program Jun 10 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a... Jun 10 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a... Jun 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK